CD4+ T cell priming accelerates the clearance of Sendai virus in mice, but has a negative effect on CD8+ T cell memory.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

CD4+ T cell priming accelerates the clearance of Sendai virus in mice, but has a negative effect on CD8+ T cell memory.

J Immunol. 2000 Mar 15;164(6):3274-82. Unique Identifier : AIDSLINE MED/20171530
Zhong W; Marshall D; Coleclough C; Woodland DL; Trudeau Institute, Saranac Lake, NY 12983, USA.

Abstract: Current vaccines designed to promote humoral immunity to respiratory virus infections also induce potent CD4+ T cell memory. However, little is known about the impact of primed CD4+ T cells on the immune response to heterologous viruses that are serologically distinct, but that share CD4+ T cell epitopes. In addition, the protective capacity of primed CD4+ T cells has not been fully evaluated. In the present study, we addressed these two issues using a murine Sendai virus model. Mice were primed with an HN421-436 peptide that represents the dominant CD4+ T cell epitope on the hemagglutinin-neuraminidase (HN) of Sendai virus. This vaccination strategy induced strong CD4+ T cell memory to the peptide, but did not induce Abs specific for the Sendai virus virion. Subsequent Sendai virus infection of primed mice resulted in 1) a substantially accelerated virus-specific CD4+ T cell response in the pneumonic lung; 2) enhanced primary antiviral Ab-forming cell response in the mediastinal lymph nodes; and 3) accelerated viral clearance. Interestingly, the virus-specific CD8+ T cell response in the lung and the development of long-term memory CD8+ T cells in the spleen were significantly reduced. Taken together, our data demonstrate that primed CD4+ T cells, in the absence of pre-existing Ab, can have a significant effect on the subsequent immune responses to a respiratory virus infection.

Keywords: JOURNAL ARTICLE Adjuvants, Immunologic/ADMINISTRATION & DOSAGE Animal Antibodies, Viral/BIOSYNTHESIS Cell Movement/IMMUNOLOGY Cytotoxicity, Immunologic CD4-Positive T-Lymphocytes/*IMMUNOLOGY/VIROLOGY CD8-Positive T-Lymphocytes/*IMMUNOLOGY/VIROLOGY Epitopes, T-Lymphocyte/ADMINISTRATION & DOSAGE/IMMUNOLOGY Female HN Protein/ADMINISTRATION & DOSAGE/IMMUNOLOGY *Immunologic Memory Leukocytosis/PATHOLOGY/VIROLOGY Lung/IMMUNOLOGY/PATHOLOGY/VIROLOGY Lymphoid Tissue/IMMUNOLOGY/VIROLOGY Mice Mice, Inbred C57BL Neutrophils/PATHOLOGY Paramyxovirus/*IMMUNOLOGY Paramyxovirus Infections/*IMMUNOLOGY/PATHOLOGY/*VIROLOGY Peptide Fragments/ADMINISTRATION & DOSAGE/IMMUNOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. T-Lymphocytes, Cytotoxic/IMMUNOLOGY

000630
A0061907

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .